<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02894541</url>
  </required_header>
  <id_info>
    <org_study_id>148FDI16004</org_study_id>
    <nct_id>NCT02894541</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Effects of Food on the Pharmacokinetics/Pharmacodynamics of CKD-519</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, 1-sequence, 3-treatment, 3-period Crossover Study to Investigate the Effects of Food on the Pharmacokinetics/Pharmacodynamics of CKD-519 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of food on the&#xD;
      pharmacokinetics/pharmacodynamics of CKD-519.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, single dose, 1-sequence, 3-treatment, 3-period crossover study to&#xD;
      investigate the effects of food on the pharmacokinetics/pharmacodynamics of CKD-519 in&#xD;
      healthy male subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of CKD-519</measure>
    <time_frame>0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of CKD-519</measure>
    <time_frame>0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of CKD-519</measure>
    <time_frame>0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of CKD-519</measure>
    <time_frame>0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of CKD-519</measure>
    <time_frame>0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of CKD-519</measure>
    <time_frame>0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vd/F of CKD-519</measure>
    <time_frame>0(predose)~168</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inhibition of CETP(Cholesteryl ester transfer protein) Activity</measure>
    <time_frame>0(predose)~168</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>CKD-519 tablet 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 tablet(formulation Ⅱ) 100mg(100mg X 1Tab) Period 1: CKD-519 100mg in fasted state Period 2:CKD-519 100mg with a standard meal Period 3:CKD-519 100mg with a high fat meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-519 tablet 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 tablet(formulation Ⅱ) 200mg(100mg X 2Tabs) Period 1:CKD-519 200mg in fasted state Period 2:CKD-519 200mg with a standard meal Period 3:CKD-519 200mg with a high fat meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-519 soft capsule 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 soft capsule(formulation Ⅲ) 100mg(100mg X 1Cap) Period 1:CKD-519 100mg in fasted state Period 2:CKD-519 100mg with a standard meal Period 3:CKD-519 100mg with a high fat meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-519 soft capsule 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 soft capsule(formulation Ⅲ) 200mg(100mg X 2Caps) Period 1:CKD-519 200mg in fasted state Period 2:CKD-519 200mg with a standard meal Period 3:CKD-519 200mg with a high fat meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519 100mg</intervention_name>
    <arm_group_label>CKD-519 tablet 100mg</arm_group_label>
    <other_name>CKD-519 tablet(formulation Ⅱ) 100mg(100mg X 1Tab)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519 200mg</intervention_name>
    <arm_group_label>CKD-519 tablet 200mg</arm_group_label>
    <other_name>CKD-519 tablet(formulation Ⅱ) 200mg(100mg X 2Tabs)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519 100mg</intervention_name>
    <arm_group_label>CKD-519 soft capsule 100mg</arm_group_label>
    <other_name>CKD-519 soft capsule(formulation Ⅲ) 100mg(100mg X 1Cap)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519 200mg</intervention_name>
    <arm_group_label>CKD-519 soft capsule 200mg</arm_group_label>
    <other_name>CKD-519 soft capsule(formulation Ⅲ) 200mg(100mg X 2Caps)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 20 aged and 45 aged in healthy adult male&#xD;
&#xD;
          -  Body weight more than 50, Body Mass Index between 18 and 29kg/m²&#xD;
&#xD;
          -  Necessarily he agrees that use double contraceptions and do not sperm donation until&#xD;
             two months during clinical trials and after the final dosage of investigational&#xD;
             products&#xD;
&#xD;
          -  Those who fully understand about this clinical trials after enough hearing, and then&#xD;
             decided to join the clinical trials by themselves and to comply with the precautions&#xD;
             written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant disease with cardiovascular, respiratory, hepatobiliary,&#xD;
             nephrological, hematological, gastrointestinal, endocrine, immune, integumentary,&#xD;
             neurologic, psychiatric system&#xD;
&#xD;
          -  Have a acute disease within 28 days before the beginning of study treatment&#xD;
&#xD;
          -  Have a disease history that can effect drug absorption, distribution, metabolism,&#xD;
             excretion&#xD;
&#xD;
          -  Have a clinically significant chronic disease&#xD;
&#xD;
          -  Systolic blood pressure&lt;100mmHg or&gt;140mmHg, diastolic blood pressure&lt;60mmHg or&gt;90mmHg&#xD;
&#xD;
          -  Defined by the following 12-lead ECG, QTc&gt;450msec&#xD;
&#xD;
          -  Positive for serology test (HBsAg, anti-HCV Ab, anti-HIV Ab, VDRL(Venereal Disease&#xD;
             Research Laboratories))&#xD;
&#xD;
          -  Subject treated ethical drug within 14 days before the beginning of study treatment&#xD;
&#xD;
          -  Subject treated over-the-counter or herbal medicine within 7 days before the beginning&#xD;
             of study treatment&#xD;
&#xD;
          -  Have a clinically significant allergic disease (except for mild allergic rhinitis,&#xD;
             allergic dermatitis with no drugs)&#xD;
&#xD;
          -  Cannot take standard Meal&#xD;
&#xD;
          -  Whole blood donation within 60 days prior to the first dosing or component blood&#xD;
             donation within 20 days prior to the first dosing&#xD;
&#xD;
          -  Blood transfusion within 30 days&#xD;
&#xD;
          -  Taking drugs have received any other investigational drug within 90 days prior to the&#xD;
             first dosing&#xD;
&#xD;
          -  Subject treated metabolizing enzyme inducers or inhibitors including barbiturates&#xD;
             within 30 days&#xD;
&#xD;
          -  Continuously taking caffeine(caffeine&gt;5 cups/day), drinking&#xD;
             alcohol(alcohol&gt;210g/week), smoking excessive cigarettes(cigarette&gt;10cigarettes/day)&#xD;
&#xD;
          -  Impossible on who participants in clinical trial by investigator's decision including&#xD;
             laboratory test result or another reasons(for example, noncompliance, a disobliging&#xD;
             manner)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Young Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea university medical center</name>
      <address>
        <city>Seoul</city>
        <state>Sungbuk-gu</state>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>September 5, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <keyword>CKD-519</keyword>
  <keyword>CETP inhibitor</keyword>
  <keyword>Food Drug Interaction</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

